U.S.-listed shares of BioNTech SE ended Monday nearly 3.2% lower, weighed down by a weak full-year revenue projection even as ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) quickly reached blockbuster status within their ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fractyl Health, Inc. Common Stock misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0.44. Operator: Good afternoon, and ...

On Thursday, Jim Cramer, the host of Mad Money, discussed the recent turbulence in the stock market, pointing to the lack of ...

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.

Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Independent directors Sarah Hofstetter, Erica Mann, and Jeffrey Smith join the Board.